Radhakrishna Kukkillaya, MD
Internal Medicine · Logan, WVNPI 1114981156
Payments from drug & device makers
Across 235 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amarin Pharma, Inc.$460
- Novo Nordisk$400
- Pfizer$236
- AbbVie$184
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$159
- plus $914 from 25 others
What the payments were for
- Food & beverage$3,424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,072 |
| Amarin Pharma, Inc. | 49 | $460 |
| Novo Nordisk | 38 | $400 |
| Pfizer | 18 | $236 |
| AbbVie | 10 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $159 |
| Abbott | 8 | $114 |
| Sunovion Pharmaceuticals Inc. | 7 | $96 |
| Amgen | 5 | $80 |
| Boehringer Ingelheim | 4 | $70 |
| Johnson & Johnson | 3 | $51 |
| Shield Therapeutics Inc | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| GSK | 2 | $30 |
| Vifor Pharma, Inc. | 2 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Si-bone, Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$106
How this compares
$3,424 in reported general payments places this provider in the 85th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 248 | $280,520 |
| OzempicSemaglutide | 109 | $201,075 |
| JardianceEmpagliflozin | 134 | $171,414 |
| MounjaroTirzepatide | 75 | $122,964 |
| FarxigaDapagliflozin Propanediol | 100 | $87,787 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $78,104 |
| JanuviaSitagliptin Phosphate | 61 | $74,652 |
| LinzessLinaclotide | 62 | $69,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $66,771 |
| TrulicityDulaglutide | 31 | $58,879 |
| EntrestoSacubitril/Valsartan | 42 | $52,187 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $48,449 |
| VascepaIcosapent Ethyl | 71 | $43,168 |
| XareltoRivaroxaban | 29 | $36,732 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 75 | $35,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $236 | $280,520248 claims |
| Novo NordiskOzempic, Novolog Mix 70-30 | $400 | $219,365153 claims |
| Boehringer IngelheimJardiance, Tradjenta | $70 | $202,302162 claims |
| Lilly USA, LLCMounjaro, Trulicity | $19 | $181,842106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,072 | $148,714166 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $30 | $82,13560 claims |
| AbbVieLinzess, Synthroid | $184 | $77,420160 claims |
| NovartisEntresto | $16 | $52,18742 claims |
| Johnson & JohnsonXarelto | $51 | $36,73229 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $159 | $15,69717 claims |
| Redhill Biopharma Inc.Movantik | $12 | $14,30725 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $34 | $13,83312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Logan
- Haytham AlkhaimyLogan$7K
- Ward PaineMorgantown$5.1M
- William ChapmanCharleston$1.7M
- Mustafa AwiliHuntington$906K
- David PickeringParkersburg$694K
- Laura DavissonMorgantown$118K
- Michael BrumageClendenin$87K
- Govind PatelFairmont$59K
- Lynn SmithLewisburg$31K
- Bisher MustafaHuntington$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.